These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1387883)

  • 1. Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.
    Nisticò P; Mortarini R; De Monte LB; Mazzocchi A; Mariani M; Malavasi F; Parmiani G; Natali PG; Anichini A
    J Clin Invest; 1992 Sep; 90(3):1093-9. PubMed ID: 1387883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An autologous T cell clone overcomes intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms: in vitro and in vivo analysis.
    Mazzocchi A; Rodolfo M; Parmiani G; Anichini A
    Melanoma Res; 1991; 1(3):169-76. PubMed ID: 1841713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.
    Anichini A; Mazzocchi A; Fossati G; Parmiani G
    J Immunol; 1989 May; 142(10):3692-701. PubMed ID: 2469723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
    de Vries JE; Spits H
    J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ; Hillstrom JR
    J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies.
    Reid I; Lundy J; Donohue JH
    J Immunol; 1992 Apr; 148(8):2630-5. PubMed ID: 1532818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-mediated redirected cytolysis against murine melanoma cells in vivo.
    Usuba O; Ito M; Bona CA; Moran TM
    Cancer Res; 1990 Sep; 50(18):6034-8. PubMed ID: 2144210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
    de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
    Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/CD3+ lymphocytes.
    Voogt PJ; Falkenburg JH; Fibbe WE; Veenhof WF; Hamilton M; Van Krimpen BA; Bolhuis RL
    J Immunol; 1989 Mar; 142(5):1774-80. PubMed ID: 2521886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific F(ab'gamma)3 antibody derivatives for redirecting unprimed cytotoxic T cells.
    Tutt A; Greenman J; Stevenson GT; Glennie MJ
    Eur J Immunol; 1991 Jun; 21(6):1351-8. PubMed ID: 1828423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted cellular immunotherapy with bifunctional antibodies.
    Nelson H
    Cancer Cells; 1991 May; 3(5):163-72. PubMed ID: 1832553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma.
    Murray JL; Gillogly M; Kawano K; Efferson CL; Lee JE; Ross M; Wang X; Ferrone S; Ioannides CG
    Cancer Res; 2004 Aug; 64(15):5481-8. PubMed ID: 15289358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
    Darrow TL; Slingluff CL; Seigler HF
    J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
    Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
    Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A; Stevenson GT; Glennie MJ
    J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines.
    Dufour E; Carcelain G; Gaudin C; Flament C; Avril MF; Faure F
    J Immunol; 1997 Apr; 158(8):3787-95. PubMed ID: 9103444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth.
    Qian JH; Titus JA; Andrew SM; Mezzanzanica D; Garrido MA; Wunderlich JR; Segal DM
    J Immunol; 1991 May; 146(9):3250-6. PubMed ID: 1826709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T lymphocyte-mediated lysis via the Fc receptor of target cells.
    Staerz UD; Bevan MJ
    Eur J Immunol; 1985 Dec; 15(12):1172-7. PubMed ID: 2935404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
    Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
    Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.